Form 4: Marinus Pharmaceuticals Executive Martha Manning Reports Stock and Option Awards

Martha Manning, SVP, General Counsel & Corporate Secretary of Marinus Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Summary

• On June 18, 2024, Martha Manning, SVP, General Counsel & Corporate Secretary of Marinus Pharmaceuticals, reported transactions involving Marinus Pharmaceuticals, Inc. [MRNS] securities.
• Manning acquired 10,918 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 49,125 shares of common stock.
• The RSUs vest in full on July 15, 2025, subject to continued service with Marinus Pharmaceuticals, Inc., and each RSU represents the right to receive one share of common stock.
• The stock options have an exercise price of $1.40 and vest in full on July 15, 2025, also subject to continued service with the Issuer, and expire on June 18, 2034.
• Following the reported transactions, Manning beneficially owns 63,884 shares of common stock and options to purchase 49,125 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards to an executive, which is a common practice in publicly traded companies.

Positives

• The grant of RSUs and stock options to a key executive could be seen as an incentive to align their interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies. It reflects changes in beneficial ownership by company insiders, which is a routine part of executive compensation and equity-based incentive programs.

Stakeholder Impact

• The grant of equity to executives can align their interests with those of shareholders, potentially driving long-term value creation.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Martha Manning, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, SEC Filing